+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemophilia Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 182 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309473

Global Hemophilia Drugs Market to Reach $22.9 Billion by 2030

The global market for Hemophilia Drugs estimated at US$15 Billion in the year 2022, is projected to reach a revised size of US$22.9 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2022-2030. Hemophilia A, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$19.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hemophilia B segment is readjusted to a revised 5.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.5 Billion, While China is Forecast to Grow at 5.2% CAGR

The Hemophilia Drugs market in the U.S. is estimated at US$4.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Select Competitors (Total 13 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics
  • Asklepios Biopharmaceutical, Inc.
  • Bayer AG
  • Biogen, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Catalyst Biosciences, Inc.
  • Chiesi Farmaceutici SpA
  • CSL Behring LLC
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Kedrion Biopharma, Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Opko Biologics
  • Pfizer, Inc.
  • rEVO Biologics, Inc.
  • Sangamo Therapeutics
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • UniQure N.V.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Hemophilia Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Hemophilia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Hemophilia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Hemophilia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Hemophilia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 5: World Recent Past, Current & Future Analysis for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 7: World 16-Year Perspective for Hemophilia A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for On-Demand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for On-Demand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for On-Demand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: USA 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: USA Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: USA 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Canada 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Canada 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
JAPAN
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Japan 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Japan 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
CHINA
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: China 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: China Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: China 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
EUROPE
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Hemophilia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Hemophilia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Europe 16-Year Perspective for Hemophilia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Europe 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Europe 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
FRANCE
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: France 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: France Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: France 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
GERMANY
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Germany 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: Germany 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Italy 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Italy 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: UK 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: UK Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: UK 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Hemophilia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
REST OF WORLD
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Hemophilia Drugs by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Hemophilia Drugs by Treatment - On-Demand and Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Hemophilia Drugs by Treatment - Percentage Breakdown of Value Sales for On-Demand and Prophylaxis for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics
  • Asklepios Biopharmaceutical, Inc.
  • Bayer AG
  • Biogen, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Catalyst Biosciences, Inc.
  • Chiesi Farmaceutici SpA
  • CSL Behring LLC
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Kedrion Biopharma, Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Opko Biologics
  • Pfizer, Inc.
  • rEVO Biologics, Inc.
  • Sangamo Therapeutics
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • UniQure N.V.

Table Information